» Articles » PMID: 20489577

Ocular Graft-versus-host Disease After Allogeneic Stem Cell Transplantation

Overview
Journal Cornea
Specialty Ophthalmology
Date 2010 May 22
PMID 20489577
Citations 46
Authors
Affiliations
Soon will be listed here.
Abstract

Purpose: To determine the prevalence and manifestations of ocular graft-versus-host disease (GvHD) after allogeneic stem cell transplantation (allo-SCT).

Methods: Prospective study of 101 consecutive patients who received allo-SCT from 2004 to 2007. All patients received ophthalmologic examination for 3 months after allo-SCT, and those with ocular complaints were evaluated at 12 and 24 months thereafter. We registered ophthalmologic and hematological data, including the indication for allo-SCT, occurrence of systemic and ocular GvHDs, ocular manifestations, and various ocular treatments.

Results: Over time, ocular GvHD developed in 54% of patients and consisted mainly of dry eyes and conjunctivitis, which increased in severity during follow-up; blepharitis and uveitis were less often encountered. Acute systemic GvHD, especially the involvement of mouth and skin, was strongly associated with ocular GvHD at 3 months (P = 0.000). Chronic GvHD was associated with the occurrence of ocular GvHD (P = 0.000), especially with the development of the dry eye. Although eye symptoms affecting activities of daily living were reported in 24 of 54 patients (44%) and 16 of 54 patients (30%) experienced temporary loss of visual acuity of more than 2 Snellen lines, only 1 developed permanent unilateral loss (counting fingers) because of ischemic vasculopathy. Cataract development was not encountered, and only 1 eye developed intraocular infection.

Conclusion: Ocular GvHD develops in a substantial part of patients after allo-SCT and decreases the activities of daily living.

Citing Articles

Clinical Manifestations and Outcomes of Ocular Graft Versus Host Disease following Allogeneic Stem Cell Transplantation.

Shetty V, Kashelkar P, Punatar S, Haldipurkar S, Hoshing A, Thakur R J Ophthalmic Vis Res. 2024; 19(3):284-296.

PMID: 39359525 PMC: 11443995. DOI: 10.18502/jovr.v19i3.13095.


A Novel Murine Model for Lupus-Like Ocular Chronic Graft-Versus-Host Disease.

Sun Y, Zhang Y, Shen J, Shi F, Li Y, Wang C Invest Ophthalmol Vis Sci. 2024; 65(6):20.

PMID: 38864812 PMC: 11174147. DOI: 10.1167/iovs.65.6.20.


A novel severity scoring system for murine ocular graft versus host disease and its correlation with CD3 T cells in the cornea.

Guasch F, Sajjan S, Tibbs E, Reandeau C, Wu L, Bohlen J Ocul Surf. 2024; 33:77-79.

PMID: 38823677 PMC: 11499683. DOI: 10.1016/j.jtos.2024.05.003.


How does ocular graft-versus-host disease fit under the dry eye umbrella? A review.

Kantor N, Tovar A, Wang T, Galor A Clin Exp Ophthalmol. 2024; 52(2):167-185.

PMID: 38204146 PMC: 10939887. DOI: 10.1111/ceo.14347.


Corneal Descemetocele Management with Multi-Layer Amniotic Membrane Transplantation in an Ocular Graft-versus-Host Disease Case.

He Y, Wong H, Gu J, Lin L Medicina (Kaunas). 2023; 59(10).

PMID: 37893451 PMC: 10607979. DOI: 10.3390/medicina59101733.